{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:06:54Z","timestamp":1777540014023,"version":"3.51.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"suppl_G","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,10,1]]},"DOI":"10.1093\/eurheartj\/sul053","type":"journal-article","created":{"date-parts":[[2006,10,3]],"date-time":"2006-10-03T11:09:28Z","timestamp":1159873768000},"page":"G35-G37","source":"Crossref","is-referenced-by-count":6,"title":["Drug interactions in the setting of acute coronary syndromes and dual anti-platelet therapy"],"prefix":"10.1093","volume":"8","author":[{"given":"Jean-Pierre","family":"Bassand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,10]]},"reference":[{"key":"key\n\t\t\t\t20171012092459_SUL053C1","doi-asserted-by":"crossref","unstructured":"Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med345:1809\u20131817.","DOI":"10.1056\/NEJMoa003199"},{"key":"key\n\t\t\t\t20171012092459_SUL053C2","doi-asserted-by":"crossref","unstructured":"Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH, Gaziano JM. (2003) Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation108:1191\u20131195.","DOI":"10.1161\/01.CIR.0000087593.07533.9B"},{"key":"key\n\t\t\t\t20171012092459_SUL053C3","doi-asserted-by":"crossref","unstructured":"MacDonald TM and Wei L. (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet361:573\u2013574.","DOI":"10.1016\/S0140-6736(03)12509-3"},{"key":"key\n\t\t\t\t20171012092459_SUL053C4","doi-asserted-by":"crossref","unstructured":"Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest126:234S\u2013264S.","DOI":"10.1378\/chest.126.3_suppl.234S"},{"key":"key\n\t\t\t\t20171012092459_SUL053C5","doi-asserted-by":"crossref","unstructured":"Coumadin Aspirin Reinfarction Study (CARS) Investigators. (1997) Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet350:389\u2013396.","DOI":"10.1016\/S0140-6736(97)01180-X"},{"key":"key\n\t\t\t\t20171012092459_SUL053C6","doi-asserted-by":"crossref","unstructured":"Buresly K, Eisenberg MJ, Zhang X, Pilote L. (2005) Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med165:784\u2013789.","DOI":"10.1001\/archinte.165.7.784"},{"key":"key\n\t\t\t\t20171012092459_SUL053C7","doi-asserted-by":"crossref","unstructured":"van Hecken A, Depre M, Wynants K, Vanbilloen H, Verbruggen A, Arnout J, Vanhove P, Cariou R, De Schepper PJ. (1998) Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. Drug Metabol Drug Interact14:193\u2013205.","DOI":"10.1515\/DMDI.1998.14.3.193"},{"key":"key\n\t\t\t\t20171012092459_SUL053C8","doi-asserted-by":"crossref","unstructured":"Clarke TA and Waskell LA. (2003) The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos31:53\u201359.","DOI":"10.1124\/dmd.31.1.53"},{"key":"key\n\t\t\t\t20171012092459_SUL053C9","doi-asserted-by":"crossref","unstructured":"Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER. (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug\u2013drug interaction. Circulation107:32\u201337.","DOI":"10.1161\/01.CIR.0000047060.60595.CC"},{"key":"key\n\t\t\t\t20171012092459_SUL053C10","doi-asserted-by":"crossref","unstructured":"Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A. (2003) Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function\u2014a flow cytometry study. Eur Heart J24:1744\u20131749.","DOI":"10.1016\/S0195-668X(03)00442-1"},{"key":"key\n\t\t\t\t20171012092459_SUL053C11","doi-asserted-by":"crossref","unstructured":"Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ. (2003) Lack of adverse clopidogrel\u2013atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation108:921\u2013924.","DOI":"10.1161\/01.CIR.0000088780.57432.43"},{"key":"key\n\t\t\t\t20171012092459_SUL053C12","doi-asserted-by":"crossref","unstructured":"Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol45:246\u2013251.","DOI":"10.1016\/j.jacc.2004.09.067"},{"key":"key\n\t\t\t\t20171012092459_SUL053C13","doi-asserted-by":"crossref","unstructured":"Wienbergen H, Gitt AK, Schiele R, Juenger C, Heer T, Meisenzahl C, Limbourg P, Bossaller C, Senges J. (2003) Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol92:285\u2013288.","DOI":"10.1016\/S0002-9149(03)00626-X"},{"key":"key\n\t\t\t\t20171012092459_SUL053C14","doi-asserted-by":"crossref","unstructured":"Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. on behalf of the CLASSICS Investigators. (2000) Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation102:624\u2013629.","DOI":"10.1161\/01.CIR.102.6.624"},{"key":"key\n\t\t\t\t20171012092459_SUL053C15","unstructured":"CAPRIE Steering Committee. (1996) A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet348:1329\u20131339."},{"key":"key\n\t\t\t\t20171012092459_SUL053C16","doi-asserted-by":"crossref","unstructured":"Serebruany VL, Malinin AI, Callahan KP, Gurbel PA, Steinhubl SR. (2001) Statins do not affect platelet inhibition with clopidogrel during coronary stenting. Atherosclerosis159:239\u2013241.","DOI":"10.1016\/S0021-9150(01)00606-2"},{"key":"key\n\t\t\t\t20171012092459_SUL053C17","doi-asserted-by":"crossref","unstructured":"Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, Tanguay JF, Steinhubl SR, Berger PB, O'Connor CM, Hennekens CH. (2004) Absence of interaction between atorvastatin or other statins and clopidogrel: results from the INTERACTION study. Arch Intern Med164:2051\u20132057.","DOI":"10.1001\/archinte.164.18.2051"},{"key":"key\n\t\t\t\t20171012092459_SUL053C18","doi-asserted-by":"crossref","unstructured":"Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ. (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA288:2411\u20132420.","DOI":"10.1001\/jama.288.19.2411"},{"key":"key\n\t\t\t\t20171012092459_SUL053C19","doi-asserted-by":"crossref","unstructured":"Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med345:494\u2013502.","DOI":"10.1056\/NEJMoa010746"},{"key":"key\n\t\t\t\t20171012092459_SUL053C20","doi-asserted-by":"crossref","unstructured":"Lim MJ, Spencer FA, Gore JM, Dabbous OH, Agnelli G, Kline-Rogers EM, Dibenedetto D, Eagle KA, Mehta RH. (2005) Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. Eur Heart J26:1063\u20131069.","DOI":"10.1093\/eurheartj\/ehi139"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/8\/suppl_G\/G35\/1544563\/sul053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T08:26:44Z","timestamp":1555835204000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article\/8\/suppl_G\/G35\/576298\/Drug-interactions-in-the-setting-of-acute-coronary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,1]]},"references-count":20,"journal-issue":{"issue":"suppl_G","published-online":{"date-parts":[[2006,10]]},"published-print":{"date-parts":[[2006,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/sul053","relation":{},"ISSN":["1554-2815","1520-1554"],"issn-type":[{"value":"1554-2815","type":"electronic"},{"value":"1520-1554","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,10]]},"published":{"date-parts":[[2006,10,1]]}}}